ARRDC3

Across TCGA pan-cancer cohorts, ARRDC3 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ARRDC3 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher ARRDC3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARRDC3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ACC and UCEC are the cancer types where ARRDC3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	III,IV	0.010	0.458	<.001	21	view →
UCEC	OS	Median	All	1.000	0.659	.017	20	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

ARRDC3–ACC (DFS)

Open the ACC breakdown →